Hemolytic uremic syndrome.
Beers
M
M
Cameron
S
S
D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000150:complications / Q000188:drug therapy; D004196:Disease Outbreaks; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000378:metabolism / Q000472:pathogenicity*; D006463:Hemolytic-Uremic Syndrome / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D007223:Infant; D009268:Nalidixic Acid / Q000009:adverse effects / Q000627:therapeutic use; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use; D011159:Population Surveillance / Q000379:methods; D011634:Public Health / Q000191:economics; D022622:Shiga Toxin 1
D000890:Anti-Infective Agents; D001427:Bacterial Toxins; D010406:Penicillins; D022622:Shiga Toxin 1; D009268:Nalidixic Acid; D000667:Ampicillin